Sodium-glucose co-transporter-2 inhibitors and cardiovascular outcome studies in people with type 2 diabetes: From efficacy to effectiveness

Diabetes Obes Metab. 2018 Apr;20(4):763-765. doi: 10.1111/dom.13142. Epub 2017 Nov 22.

Authors

Kamlesh Khunti¹, Mikhail Kosiborod²

Affiliations

¹ Diabetes Research Centre, University of Leicester, Leicester Diabetes Centre, Leicester General Hospital, Leicester, UK.
² Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, Missouri.

PMID: 29077267
DOI: 10.1111/dom.13142

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Benzhydryl Compounds
Diabetes Mellitus, Type 2*
Glucose
Glucosides
Humans
Outcome Assessment, Health Care
Sodium
Sodium-Glucose Transporter 2 Inhibitors*
Symporters*

Substances

Benzhydryl Compounds
Glucosides
Sodium-Glucose Transporter 2 Inhibitors
Symporters
Sodium
empagliflozin
Glucose